Get Your COVID-19 Vaccine Boosters

    3
    530
    Credit: CDC/ Alissa Eckert, MS; Dan Higgins, MAMS

    Health Editor’s Note: A more robust protection against the newest mutated strain (variant) of COVID-19 (Omicron) is achieved with the booster or third dose of Pfizer COVID-19 vaccine.  Everyone, whether you received the Pfizer or Moderna initial two vaccines or the J&J one dose, should all receive a booster dose. At this time you may request any one of the three types of vaccines to achieve your booster. All of the major pharmacies offer boosters either by appointment of just walk in the door with maybe a wait time or not. These boosters are free just as the initial doses were. Encourage anyone you know and care about to also get the booster or if they are not yet vaccinated, to begin their vaccination process against COVID-19.  The longer people go unvaccinated and continue to become infected with COVID-19, the more this virus will mutate and will become stronger.  Just remember successful viral mutations will make for a more lethal virus….Carol   

    Pfizer and BioNTech Provide Update on Omicron Variant

    by Pfizer

    Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers

    Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection

    As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease

    The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022

    NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.

    Read More:

    ATTENTION READERS
    Due to the nature of independent content, VT cannot guarantee content validity.
    We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

    All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

    About VT - Read Full Policy Notice - Comment Policy

    3 COMMENTS

    1. We need to shut down and prosecute the weath-care pandemic creators, not buy the dangerous vaccines that often cause death and serious injuries.

    Comments are closed.